Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
PMVPthis companyPMV Pharmaceuticals, Inc.	$1.28	-0.84×	0.63×	0×	-0.36×	-52.3%	0.0%	0.0%	0.0%	-74.2%	-79.5%	-112.1%	0.01×	0.47×	0×	10.09×	0.0%	1	-6.12	3	B-
ACRVAcrivon Therapeutics, Inc. Common Stock	$1.64	-1.19×	0.82×	0×	-0.71×	-40.7%	0.0%	0.0%	0.0%	-69.2%	-73.0%	-70.4%	0.02×	0.51×	0×	7.69×	0.0%	1	-2.78	3	B-
ATYRaTyr Pharma, Inc.	$7.26	-0.98×	1.08×	383.2×	-1.02×	-128.4%	-717.4%	-40856.3%	-39009.5%	-109.8%	-96.5%	-85.2%	0.18×	-0.02×	0×	5.3×	0.0%	2	-14.23	2	C
BMEABiomea Fusion, Inc.	$0.60	-1.05×	2.19×	0×	-0.17×	48.4%	0.0%	0.0%	0.0%	-209.1%	-166.2%	-108.7%	0.05×	0.9×	0×	5.23×	0.0%	0	-18.95	2	C+
CBUSCibus, Inc.	$1.25	-0.63×	3.65×	21.88×	-3.72×	-625.8%	-62.8%	-1853.9%	-3492.3%	-582.2%	-23.2%	-64.3%	12.28×	-2.84×	-1.9×	0.72×	0.0%	3	-4.45	1	D+
IMUXImmunic, Inc.	$8.02	-0.86×	-12.46×	0×	-0.7×	-91.8%	0.0%	0.0%	0.0%	1456.2%	1693.4%	-103.4%	-0.1×	0.15×	0×	0.75×	0.0%	2	-5.39	2	C
Peer median	—	-0.98×	1.08×	0×	-0.71×	-91.8%	0.0%	0.0%	0.0%	-109.8%	-73.0%	-85.2%	0.05×	0.15×	0×	5.23×	0.0%	2	-5.39	2	—